Form 4: Suvretta Capital Management and Affiliates Increase Stake in Benitec Biopharma Inc.

Suvretta Capital Management, along with Averill Master Fund, Averill Madison Master Fund, and Aaron Cowen, reported increased beneficial ownership of Benitec Biopharma Inc. common stock through open market purchases.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., and Aaron Cowen (collectively, the Reporting Persons) filed a Form 4 detailing changes in their beneficial ownership of Benitec Biopharma Inc. (BNTC) common stock.
• The Reporting Persons, including entities managed by Suvretta Capital, made open market purchases of BNTC common stock on December 23 and 24, 2024.
• Averill Master Fund purchased 24,360 shares at an average price of $10.98 and 17,730 shares at an average price of $11.25.
• Averill Madison Master Fund purchased 3,142 shares at an average price of $10.98 and 2,288 shares at an average price of $11.25.
• These transactions resulted in increased indirect beneficial ownership of BNTC shares by the Reporting Persons.
• Following these transactions, Averill Master Fund beneficially owns 7,999,455 shares and Averill Madison Master Fund beneficially owns 960,554 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a factual report of stock purchases. The increased investment could be seen as a positive signal, but it's not explicitly stated as such.

Positives

• Increased investment by Suvretta Capital and its affiliates may signal confidence in Benitec Biopharma's future prospects.
• The open market purchases suggest a belief that BNTC shares are undervalued at the acquisition prices.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and significant shareholders, providing transparency to the market.

Comparison to Industry Standards

• The filing is consistent with SEC regulations regarding insider trading and beneficial ownership reporting.
• Similar filings are common for institutional investors like Suvretta Capital when they adjust their positions in publicly traded companies.
• The level of detail provided in the explanation of responses is standard for Form 4 filings involving multiple entities and indirect ownership.

Stakeholder Impact

• Shareholders may view the increased stake by Suvretta Capital as a positive sign, potentially influencing the stock price.
• The increased investment could provide Benitec Biopharma with additional financial flexibility.

Key Dates